Paris-based healthtech startup Biolevate has raised €6 million in a Seed funding round led by EQT Ventures, marking a significant milestone in its mission to transform the labor-intensive process of medical writing with artificial intelligence (AI).

The company's platform leverages natural language processing (NLP) and visual document reading to assist medical writers in creating high-quality documentation, a crucial step in the development of new drugs. This innovative approach aims to address the severe shortage of expert writers and the administrative burden on pharmaceutical companies, which must create extensive documentation to satisfy regulators.

According to CEO Joel Belafa, the idea for Biolevate was born out of his 25-year friendship with COO Nathan Chen, who shared his frustration with the slow and difficult R&D and market access processes for therapeutic products. Belafa's expertise in AI for enterprises, combined with Chen's understanding of pharmaceutical processes, formed the foundation of the company's first prototype, Elise.

The platform has since caught the attention of industry experts, including Anas Laaroussi and Antoine De Torcy, who joined as CTO and CPO, respectively. Biolevate's solution optimizes the creation and management of research and compliance documents, effectively working as an AI assistant to medical writers. This collaboration enables writers to focus on high-value tasks, reducing the time and effort needed to understand or correct the system.

Biolevate's innovative approach has earned it a spot on Station F's Future 40 list, recognizing the company's potential to drive significant change in the biotech industry. Julien Hobeika, Partner at EQT Ventures, praised the team's impressive solution, stating that it has the potential to transform medical documentation processes into a seamless and effective procedure that supports innovation and drives scientific breakthroughs benefiting society.

In the event that the company's current strategy does not yield the desired results, Belafa outlined alternative plans, including commercializing the platform as a service for other industries, selling individual models as an API, or offering a drug discovery professional service. This flexibility demonstrates Biolevate's commitment to adapting to the evolving needs of the biotech industry.

As the pace of drug development continues to accelerate with the help of AI, Biolevate's platform is poised to play a critical role in streamlining the documentation process. With its €6 million Seed funding, the company is well-positioned to further develop its innovative solution and make a meaningful impact on the biotech industry.